From a multi-billion-pound boost to R&D and life sciences manufacturing, to scaling innovative businesses through the British Business Bank, the Review signals significant investment.
In this webinar, get a comprehensive overview of the UK’s biotech and life sciences presence at BIO 2025. Learn about the UK delegation’s plans, including the UK Pavilion organised by the Department for Business and Trade.
UK biotech financing in Q1 2025 saw a sharp rise in overall equity financing, reaching £924 million across venture capital and follow-on funding. This represents a modest decline compared to £987 million in Q1 2024 but masks a shift in where capital is flowing.
BIA has responded to the DBT's consultation on potential UK tariffs in response to US measures, urging to protect life sciences supply chains, innovation, and patient access.
Following a number of ‘firsts’ for Stablepharma during 2024, we spoke with Ozgur Tuncer, CEO and Executive Director about a year that has accelerated the commercialisation of the world’s first fridge-free vaccine, SPVX02, for the prevention of Tetanus and Diphtheria.
The UK biotech sector secured an impressive £808 million in Q3 2024, defying tough global market conditions and demonstrating sustained investor confidence. Read our latest report to find out more.
2024 continues to be a big year for US politics. As well as a presidential election, there are several pieces of legislation that either are affecting or will affect our sector. Watch the recording to learn more about all three of these developments, and what it will mean for you as a UK biotech.
The BIA’s policy and public affairs team attended the conferences of the three major UK parties this year. This is a key point in the political calendar and allows us to highlight the sector through fringe events, meet policymakers, and get a sense of the political environment.
NHS England has published a consultation document which sets out proposals for updating the NHS Commercial Framework for New Medicines. The BIA has responded to the consultation on updating the NHS commercial framework for new medicines.
